TransCode Therapeutics (RNAZ)
(Delayed Data from NSDQ)
$1.34 USD
+0.22 (19.64%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $1.33 -0.01 (-0.75%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
TransCode Therapeutics Inc. [RNAZ]
Reports for Purchase
Showing records 1 - 13 ( 13 total )
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
IND Cleared for Phase 1/2 Study of TTX-MC138 in Solid Tumors
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
4Q23 Recap: Phase 1 TTX-MC138 Study Expected to Initiate in Mid-2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
Data at SABCS Demonstrate That TTX-MC138 Is Delivered to Metastases in Phase 0 Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
3Q23 Recap: Phase 0 Study Continues to Enroll Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
First Patient Dosed in Phase 0 Study Confirms TTX-MC138 Traffics to Metastatic Lesions
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
2Q23 Recap: Phase 0 Study to Initiate Dosing Patients Soon; Phase 1/2 IND-Filing on Track for YE23
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
TTX-MC138 Phase 0 Study to Initiate Imminently; Updating Model Post Reverse Stock Split
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
Noteworthy Discussion Points From Our Meetings at
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
With TTX-MC138 eIND Cleared, the Company''s First Clinical Trial Is Set to Initiate in 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
eIND Submission Puts TTX-MC138 One Step Closer to the Clinic
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
3Q22 Take: eIND Filing on Track for 4Q22; Lowering PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
2Q22 Take: eIND Filing and Phase 0 Initiation for TTX-MC138 is the Focus in 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
Cracking the Code for Delivering RNA Therapeutics to Tumors; Initiating at Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
|